|Vertex Announces Interim Phase 2 Data on CFTR. PDL Lowers Q2 2011 Revenue.|
|By Staff and Wire Reports|
|Thursday, 09 June 2011 18:36|
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, their lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.
The first part of the study met its two primary endpoints: safety and tolerability of the combination regimen and the effect of the combination of VX-770 and VX-809 on CFTR function as measured by sweat chloride, a key measure of the function of the CFTR protein.
VX-809, known as a CFTR corrector, is designed to help the protein reach the cell surface, while VX-770, known as a CFTR potentiator, aims to help the protein function more normally once it reaches the cell surface. VX-770 and VX-809 were advanced into development with support from Cystic Fibrosis Foundation Therapeutics, Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation.
The first part of the study enrolled and randomized 62 people with two copies of the most common mutation in the CF gene, known as the F508del mutation.
PDL BioPharma Inc. (NASDAQ:PDLI), revised its guidance for the second quarter of 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.
The revision to the earlier guidance of $128 million is due to a mathematical error.
ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (OTCQB:APCSF) -On May 30, 2011, the Canadian Medical Association published an article indicating that two new "superbugs", Morganella morganii, and Providencia rettgeri, have spontaneously emerged in patients in Ontario.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, is scheduled to present at the William Blair Growth Stock Conference at the Four Seasons Hotel in Chicago, Illinois on Wednesday, June 15, 2011.
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it will exhibit for the first time in the U.S. its newly branded Magellan™ Vascular Robotic System at the 2011 Vascular Annual Meeting® of the Society for Vascular Surgery® from June 15-18 at McCormick Place Lakeside Center in Chicago.
Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that Lpath has been issued a key patent to add to its expanding patent portfolio, which has grown now by six patents over the last six months.
Medical Marijuana Inc (PINKSHEETS: MJNA) and CannaBANK™ are proud to announce the signing of a managed services contract with a California-based cooperative of 7,200+ qualified patient members.
Quest Diagnostics Incorporated (NYSE:DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa™ molecular diagnostic test on the 3M™ Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday in New York City.
Regenicin, Inc (OTCBB: RGIN) announced today that an agreement was reach between the company and its former president Mr. Joseph Connell.
Synthes, Inc. (SIX: SYST.VX) and Eli Lilly and Company (NYSE:LLY) today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.
TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that TomoTherapy shareholders have approved the Agreement and Plan of Merger, dated as of March 6, 2011, which provides for the acquisition by Accuray Incorporated (NASDAQ: ARAY) of all of the outstanding shares of TomoTherapy.
Regenicin, Inc. (OTCBB: RGIN) announced today that an arrangement has been reached between the Company and its former president, Mr. Joseph Connell, to dismiss the Company and members of its board of directors from the lawsuit he brought, now pending in the US District Court for the Southern District of New York.